India and China clear needle-free COVID-19 vaccines

Sep 5, 2022, 8:23 PM | Updated: Sep 6, 2022, 8:46 am

FILE- An employee of Bharat Biotech speaks on a mobile phone inside a bus on the outskirts of Hyder...

FILE- An employee of Bharat Biotech speaks on a mobile phone inside a bus on the outskirts of Hyderabad, India, Saturday, Jan. 9, 2021. India on Tuesday, Sept. 6, 2022, cleared a new approach to COVID-19 vaccination, a nasal version designed to fight the virus right where it enters the body. The vaccine was developed by scientists at Washington University in St. Louis and later licensed to Indian vaccine maker Bharat Biotech. (AP Photo/Mahesh Kumar A., File)

(AP Photo/Mahesh Kumar A., File)


              FILE- A health worker screens people for COVID-19 symptoms at Dharavi, one of Asia's biggest slums, in Mumbai, India, Monday, July 6, 2020. India on Tuesday, Sept. 6, 2022, cleared a new approach to COVID-19 vaccination, a nasal version designed to fight the virus right where it enters the body. It may be easier to administer a squirt in the nose than a shot, especially in low-income countries, said Dr. Michael Diamond of Washington University in St. Louis, who helped create the vaccine licensed to Bharat. (AP Photo/Rafiq Maqbool, File)
            
              FILE- A health worker takes a nasal swab sample of a woman to test for COVID-19 before she receives the vaccine in Gauhati, India, Friday, June 18, 2021. India on Tuesday, Sept. 6, 2022, cleared a new approach to COVID-19 vaccination, a nasal version designed to fight the virus right where it enters the body. The vaccine was developed by scientists at Washington University in St. Louis and later licensed to Indian vaccine maker Bharat Biotech. (AP Photo/Anupam Nath)
            
              FILE- An employee of Bharat Biotech speaks on a mobile phone inside a bus on the outskirts of Hyderabad, India, Saturday, Jan. 9, 2021. India on Tuesday, Sept. 6, 2022, cleared a new approach to COVID-19 vaccination, a nasal version designed to fight the virus right where it enters the body. The vaccine was developed by scientists at Washington University in St. Louis and later licensed to Indian vaccine maker Bharat Biotech. (AP Photo/Mahesh Kumar A., File)

NEW DELHI (AP) — India and China have cleared a new approach in COVID-19 vaccination — two needle-free options, one a squirt in the nose and the other inhaled through the mouth.

Regulators in India authorized Bharat Biotech’s nasal version on Tuesday as an option for people who haven’t yet been vaccinated.

“This step will further strengthen our collective fight against the pandemic,” Indian health minister Mansukh Mandaviya said on Twitter.

It’s not clear how well the nasal version works. Bharat didn’t immediately release results of its studies or say how soon the new option will roll out.

CanSino Biologics announced Sunday that Chinese regulators have approved an inhaled version of the company’s injected COVID-19 vaccine to be used as a booster dose. The company pointed to preliminary results of studies suggesting the inhaled version revved up immune protection after one puff. It’s not clear if that translated to improved effectiveness, or how soon the inhaled booster will be available.

COVID-19 vaccines today are shots, and they’ve saved millions of lives and continue to offer strong protection against severe illness and death, even as more contagious variants of the coronavirus circulate.

But shot-free versions are being explored as a strategy to improve protection against infection, with particular interest in nasal vaccines designed to fend off the virus right where it enters the body. Nearly a dozen possible candidates are in various stages of testing globally, and CanSino’s is one of two inhaled vaccine candidates being developed, according to the World Health Organization.

India’s nasal vaccine was developed by scientists at Washington University in St. Louis and later licensed to Indian vaccine maker Bharat Biotech. The company conducted two trials, giving two doses of the vaccine to 3,100 previously unvaccinated volunteers and as a booster to around 875 volunteers who had received two shots of other COVID-19 vaccines.

Bharat also is seeking clearance for the nasal spray to be used as a booster for the two-thirds of people in India who’ve already been vaccinated.

Bharat’s nasal spray uses a harmless chimpanzee cold virus to deliver a copy of the coronavirus spike protein to the lining of the nose, training the body to react if it encounters the real virus.

CanSino’s inhaled booster uses a similar harmless human cold virus — it’s the company’s one-dose injected vaccine turned into an aerosolized form. The inhaled vaccine was largely tested as a booster for people who had received another Chinese company’s COVID-19 shots.

Ashley St. John, who is an immunologist at the Duke-NUS Medical School in Singapore, said scientists are pursuing nasal and inhaled COVID-19 vaccine options because the immune system has specialized tools to protect different sites in our body in slightly different ways.

“The advantage with nasal vaccines is that it may get rid of the virus before it has a chance to establish itself in the lungs and replicate,” said Dr. Vineeta Bal, an immunologist and professor at the Indian Institute of Science Education Research in Pune city.

The advantages that vaccines sprayed through the mouth have will depend on the size of individual droplets in the spray, Bal added. Large droplets would train defenses in the mouth and parts of the throat, while smaller droplets are expected to travel deeper and reach the lungs.

It also may be easier to administer a squirt in the nose than a shot, especially in low-income countries, said Dr. Michael Diamond of Washington University in St. Louis, who helped create the vaccine licensed to Bharat.

In October 2021, Russia’s Health Ministry allowed early trials of a nasal form of Sputnik V among 500 volunteers, but the status of those trials and the availability of the vaccine remains unclear.

Vaccination rates in India have dipped in the past months with detected cases plateauing. Around 940 million people, or 67% of the population, have received the first two shots, but only 15% of them have received a third booster shot.

___

AP Medical Writer Lauran Neergaard contributed to this report.

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

AP

FILE - OpenAI's CEO Sam Altman gestures while speaking at University College London as part of his ...

Associated Press

OpenAI boss ‘heartened’ by talks with world leaders over will to contain AI risks

OpenAI CEO Sam Altman said Monday he was encouraged by a desire shown by world leaders to contain any risks posed by the artificial intelligence technology his company and others are developing.

1 day ago

FILE - The draft of a bill that President Joe Biden and House Speaker Kevin McCarthy of Calif., neg...

Associated Press

Debt deal imposes new work requirements for food aid and that frustrates many Democrats

Democrats are deeply conflicted about the debt ceiling deal, fearing damage has been done to safety net programs

2 days ago

Seattle lawyer...

Associated Press

Lawsuit alleging ex-deputy falsified arrest report settled for $250K

A lawsuit filed by a Washington oyster farmer accusing a former county deputy of falsifying an arrest report

2 days ago

Mt. Rainier death...

Associated Press

Washington man climbing Mount Rainier dies near summit

A Washington state man who was trying to summit Mount Rainier this week collapsed and died near the top of the mountain.

4 days ago

biden crisis averted...

Zeke Miller and Chris Megerian

Biden celebrates a ‘crisis averted’ in Oval Office address on bipartisan debt ceiling deal

President Joe Biden celebrated a “crisis averted” in his first speech to the nation from the Oval Office Friday evening.

4 days ago

Margrethe Vestager, Executive Vice-President for A Europe Fit for the Digital Age and Competition, ...

Associated Press

US, Europe working on voluntary AI code of conduct as calls grow for regulation

The United States and Europe are drawing up a voluntary code of conduct for artificial intelligence as the developing technology triggers warnings

4 days ago

Sponsored Articles

Men's Health Month...

Men’s Health Month: Why It’s Important to Speak About Your Health

June is Men’s Health Month, with the goal to raise awareness about men’s health and to encourage men to speak about their health.

Internet Washington...

Major Internet Upgrade and Expansion Planned This Year in Washington State

Comcast is investing $280 million this year to offer multi-gigabit Internet speeds to more than four million locations.

Compassion International...

Brock Huard and Friends Rally Around The Fight for First Campaign

Professional athletes are teaming up to prevent infant mortality and empower women at risk in communities facing severe poverty.

Emergency Preparedness...

Prepare for the next disaster at the Emergency Preparedness Conference

Being prepared before the next emergency arrives is key to preserving businesses and organizations of many kinds.

SHIBA volunteer...

Volunteer to help people understand their Medicare options!

If you’re retired or getting ready to retire and looking for new ways to stay active, becoming a SHIBA volunteer could be for you!

safety from crime...

As crime increases, our safety measures must too

It's easy to be accused of fearmongering regarding crime, but Seattle residents might have good reason to be concerned for their safety.

India and China clear needle-free COVID-19 vaccines